Skip to main content Skip to search Skip to main navigation

Latest News from PIC/S

From 6 to 7 November 2023, the PIC/S Committee Meeting took place in Bangkok, Thailand, chaired by Paul Gustafson from Health Canada. The Ministry of Public Health of the Thai Food and Drug Administration (Thai FDA) hosted the meeting.

The meeting was attended by 37 of the 56 Participating Authorities (PAs) as well as various applicants, pre-applicants and partner organisations.

The most important aspects in brief:

DFA submits application for pre-accession

  • The Egyptian Medicines Agency EDA applied for PIC/S pre-accession on 22 September 2023.
  • This step involves an assessment by the PIC/S to identify potential discrepancies between the PIC/S membership requirements and the applicant regulatory authority's system. The PIC/S Committee then decides on further steps, e.g. on a possible application for membership.
  • The appointment of the rapporteur, who accompanies and supervises the pre-accession process, takes place via a written procedure.

China's NMPA has applied for membership

  • On 22 September 2023, China's National Medical Products Administration (NMPA) submitted its application for the PIC/S membership, which was completed on 3 November 2023. The pre-accession procedure was initiated on 24 September 2021.
  • The regulatory authority represents all Chinese authorities that participate in the Chinese Good Manufacturing Practice Regulatory Compliance Programme (GMPRCP) of the PIC/S.
  • Jacques Morénas from the French authority ANSM has been appointed as rapporteur. He will lead the PIC/S audit team overseeing the accession process.

Memorandum of Understanding with the ICH

  • In October 2023, a Memorandum of Understanding (MoU) between the PIC/S and the International Council for Harmonisation (ICH) was signed.
  • The MoU aims to ease the cooperation on ICH guidelines of relevance to inspection activities and to provide training for assessors and inspectors.
  • As both organisations are active in the field of harmonisation of medicinal products, it is not the first rapprochement. The PIC/S holds observer status with the ICH since 2017, and many ICH regulatory members are themselves PAs with the PIC/S.

A new PIC/S chair for the period 2024-2025 was also elected at the committee meeting in early November. The committee voted unanimously for Mr Jacques Morénas.


Source:

PIC/S: Newsroom

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: Updated Q&A on OOS Batches of ATMPs

EMA: Updated Q&A on OOS Batches of ATMPs

The EMA has revised its questions and answers on the use of out-of-specification (OOS) batches of authorised cell- and tissue-based ATMPs (“Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based ATMPs”, Rev. 1, 2026).
Read more
Previous
Next